Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 661 of the 661 references it cites were found in a registry or an index; 149 of the 565 sources its claims cite were checked for support.
Abstract
Alzheimer’s disease (AD) is the most common neurodegenerative disorder seen in age-dependent dementia. There is currently no effective treatment for AD, which may be attributed in part to lack of a clear underlying mechanism. Studies within the last few decades provide growing evidence for a central role of amyloid β (Aβ) and tau, as well as glial contributions to various molecular and cellular pathways in AD pathogenesis. Herein, we review recent progress with respect to Aβ- and tau-associated mechanisms, and discuss glial dysfunction in AD with emphasis on neuronal and glial receptors that mediate Aβ-induced toxicity. We also discuss other critical factors that may affect AD pathogenesis, including genetics, aging, variables related to environment, lifestyle habits, and describe the potential role of apolipoprotein E (APOE), viral and bacterial infection, sleep, and microbiota. Although we have gained much towards understanding various aspects underlying this devastating neurodegenerative disorder, greater commitment towards research in molecular mechanism, diagnostics and treatment will be needed in future AD research.
Overview
CoChat Summary
TL;DR
This review synthesizes molecular and cellular mechanisms of Alzheimer’s disease, emphasizing Aβ and tau pathology, glial dysfunction, and genetic, environmental, and lifestyle contributors. It concludes that AD pathogenesis is multifactorial and that no effective disease-modifying treatment exists, with current drugs only symptomatic.
Key findings
- Aβ is generated by APP cleavage; Aβ42 is the main amyloid plaque component and is neurotoxic, while oligomeric Aβ mediates synaptotoxicity through neuronal receptors including NMDAR, EphB2, EphA4, PrPC, and LilrB2, and through mitochondrial dysfunction.
- Tau pathology involves post-translational modifications, aggregation, prion-like propagation, and neurotoxicity; Aβ acts upstream of and synergistically with tau, and tau is required for Aβ-induced neurotoxicity in several models.
- Glial contributions include microglial receptors such as TREM2, LRP1, TLR2/4, CR3, CD36, and RAGE; astrocytic receptors such as α7nAChR and CaSR; glymphatic dysfunction; and neuroinflammation.
- Genetic and environmental factors include APOE ε4 (global frequency 13.7%, rising to 40% in AD patients), heritability estimated at ~60–80%, >95% sporadic AD, HSV risk increased 1.3-fold and 2.7-fold in concurrent HSV-1/APOE4 carriers, CAA prevalence up to 80–90%, and only five FDA-approved AD drugs with no new approvals since 2003.
Methods
- Narrative review of recent progress on Aβ- and tau-associated mechanisms, glial dysfunction, and other AD contributors; no primary experiments or systematic review/meta-analysis are described.
- Synthesizes evidence from human AD brain, CSF/blood biomarkers, cell culture, animal models (transgenic mice/rats, Drosophila, nonhuman primates), and clinical trial literature.
- Main analysis is qualitative integration of molecular and cellular pathways into proposed models (Figs. 1 and 2).
Limitations
- Stated: incomplete understanding of AD pathophysiology; most AD models carry familial early-onset mutations and may not model sporadic AD (>95% of cases); clinical trials often treat late/irreversible stages; no effective disease-modifying drugs exist.
- Stated: several mechanisms remain controversial or unclear, including the tau 3R:4R ratio in AD, TREM2’s role in tau pathogenesis, AEP-cleaved tau, tau LLPS in vivo, and non-coding RNA roles.
- Evident: as a narrative review, it does not provide a systematic search strategy, risk-of-bias assessment, or quantitative synthesis; conclusions depend on the cited literature.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
83 Valid · 8 Not valid · 267 Not checked · 59 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“PrPC deletion functionally restored synaptic LTP deficits induced by oAβ in different AD mouse models, such as APP/PS1 (APPswe /PSEN1△E9) [89].”
§ Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease > Aβ and AD pathogenesis > oAβ associated-receptors in neurons
What the sources say
- Disputedcites [89] Gimbel DA, et al. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J Neurosci. 2010;30(18):6367–74. sourceExperimental — accuracy not yet measured
The Results report no LTP deficit in the APPswe/PSen1ΔE9 mice, so there was no LTP deficit for PrPC deletion to restore in that model. The paper instead reports rescue of spatial-memory deficits and other phenotypes; it describes acute Aβ-induced LTP suppression in hippocampal slices as a finding from previous work. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“only caspase-2, 3 and 6 cleaved tau products have been linked to AD [190–193].”
§ Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease > Tau and AD pathogenesis > Post-translational modifications of tau
What the sources say
- Not checked yetcites [190] Zhao X, et al. Caspase-2 cleavage of tau reversibly impairs memory. Nat Med. 2016;22(11):1268–76. source
- Partly supportedcites [191] Gamblin TC, et al. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer’s disease. Proc Natl Acad Sci U S A. 2003;100(17):10032–7. sourceExperimental — accuracy not yet measured
The Results show tau truncated at Asp421 in AD pathology and show that caspases 3 and 6 can cleave tau in vitro. They do not identify which caspase produced the tau found in AD brain. The Results do not report cleavage by caspase-2, and the paper does not establish that only the three named caspases have AD-linked cleavage products. (LLM, conf=0.86)
- Disputedcites [192] Rissman RA, et al. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest. 2004;114(1):121–30. sourceExperimental — accuracy not yet measured
The section “Tau is cleaved at D421 by executioner caspases” (page unavailable) says both caspase-3 and caspase-7 generate the ΔTau fragment; the paper then links ΔTau to Alzheimer disease tangle pathology. This runs against the claim’s exclusive list of caspases 2, 3 and 6. The paper does not establish caspase-2 or caspase-6 cleavage of tau. (LLM, conf=0.82)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [193] Guo H, et al. Active caspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer’s disease. Am J Pathol. 2004;165(2):523–31. sourceExperimental — accuracy not yet measured
The Results and Discussion report caspase-6-cleaved tau in AD and discuss detection of caspase-3-cleaved tau in AD lesions. Our copy does not link caspase-2-cleaved tau to AD or establish that these are the only three caspase-cleaved tau products linked to AD. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Both full-length and truncated tau isoforms can be secreted.”
§ Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease > Tau and AD pathogenesis > Post-translational modifications of tau
What the sources say
- Disputedcites [216] Johnson GV, et al. The tau protein in human cerebrospinal fluid in Alzheimer’s disease consists of proteolytically derived fragments. J Neurochem. 1997;68(1):430–3. sourceExperimental — accuracy not yet measured
The Results (page not available in our copy) report tau fragments in human CSF but no intact tau, including in samples collected with protease inhibitors. The Discussion likewise describes CSF tau as truncated rather than intact. These findings run contrary to citing this paper for secretion of both forms, although the study does not rule out full-length tau secretion in other settings. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [217] Meredith JE Jr, et al. Characterization of novel CSF tau and ptau biomarkers for Alzheimer’s disease. PLoS One. 2013;8(10):e76523. sourceExperimental — accuracy not yet measured
The Introduction reports evidence that tau can be actively secreted, and the Results identify truncated tau fragments in CSF. But the paper does not establish that full-length tau is secreted: its Results report no detectable full-length tau in the CSF samples, while the Discussion describes earlier reports of full-length tau as mixed and potentially affected by artifacts. (LLM, conf=0.85)
- Not checked yetcites [218] Sato C, et al. Tau kinetics in neurons and the human central nervous system. Neuron. 2018;98(4):861–4. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“It is therefore likely that AEP plays a role in regulating tau degradation, rather than enhancing tau aggregation [212, 213, 215].”
§ Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease > Tau and AD pathogenesis > Post-translational modifications of tau
What the sources say
- Disputedcites [212] Zhang Z, et al. Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer’s disease. Nat Med. 2014;20(11):1254–62. sourceExperimental — accuracy not yet measured
The Results section ('AEP-generated tau fragments form insoluble fibrils in vitro'; page unavailable) says AEP cleavage produces fragments that elicit tau aggregation. The paper supports AEP-mediated tau degradation, but contradicts the claim’s contrast that AEP regulates degradation rather than enhancing aggregation. (LLM, conf=0.92)
Checked by a reasoning model — may be wrong.
- Not checked yetcites [213] Behrendt A, et al. Asparagine endopeptidase cleaves tau at N167 after uptake into microglia. Neurobiol Dis. 2019;130:104518. source
- Disputedcites [215] Zhang Z, et al. Inhibition of delta-secretase improves cognitive functions in mouse models of Alzheimer’s disease. Nat Commun. 2017;8:14740. sourceExperimental — accuracy not yet measured
The Abstract (page not provided) says that AEP, also called δ-secretase, cleaves tau and induces tau aggregation—the opposite of the claim’s contrast with aggregation. The Discussion (page not provided) adds that the resulting tau fragments can promote neurofibrillary tangle deposition. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, it has been shown that the levels of Aβ38, Aβ42 and the Aβ42/Aβ38 ratio in cerebral spinal fluid (CSF) can be used to distinguish AD from other dementias [32–34].”
§ Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease > Aβ and AD pathogenesis > APP processing
What the sources say
- Not checked yetcites [32] Welge V, et al. Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer’s disease. J Neural Transm (Vienna). 2009;116(2):203–12. source
- Not checked yetcites [33] Tang W, et al. Assessment of CSF Abeta42 as an aid to discriminating Alzheimer’s disease from other dementias and mild cognitive impairment: a meta-analysis of 50 studies. J Neurol Sci. 2014;345(1–2):26–36. source
- Partly supportedcites [34] Mulugeta E, et al. CSF amyloid beta38 as a novel diagnostic marker for dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2011;82(2):160–4. sourceExperimental — accuracy not yet measured
The Results (p. 3) report that Aβ38 and the Aβ42/Aβ38 ratio differed between AD and DLB, with the ratio providing the best discrimination. But Aβ42 did not differ between those groups, and the study does not establish that all three measures distinguish AD from other dementias generally. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
244 more claims · 51 with their cited sources checked
Create a free account to see all 417 claims and to verify the 416 references still open.
- It may state two separate claims as one. 159
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Factors contributing to the suboptimal performance of drugs include the selection of drug targets, the use of biomarkers and animal models in experimental designs, and other issues such as late treatment initiation, dose-dependent side effects, challenges in BBB permeability, and the heterogeneous presentation of patients.182,479,480”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [182]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Apolipoprotein E (ApoE) also plays a key role in the microglia-dependent and astrocyte-dependent regulation of tau pathology and tau-induced neurodegeneration [41,42].”
From Role of Tau Protein in Neurodegenerative Diseases and Development of Its Targeted Drugs: A Literature Review (2024) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD is not driven by a single pathological process but rather by complex interactions among neurons and glial cells—including astrocytes, microglia, and oligodendrocytes—that contribute to synaptic dysfunction, neuroinflammation, white matter injury, and neuronal loss.”
From Diffusion MRI reveals amyloid plaque–associated cellular signatures through spatial transcriptomic integration (2026) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“ApoE4 is able to directly interact with both soluble and fibrillar forms of Aβ [17,38], accelerating its oligomerization and deposition in the brain [2].”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Even though the global frequency of ApoE4 is approximately 13.7%, around 40% of all AD patients carry at least one copy of the ε4 allele [2].”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [2]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease > Glial contributions to AD pathogenesis > Astrocytic receptors
“Excreted glutamate can activate extrasynaptic NMDAR in neurons residing within neuron/astrocyte conjugates, resulting in Ca2+ efflux.”
§ Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease > Aβ and AD pathogenesis > oAβ associated-receptors in neurons
“Similar to NMDA stimulation, Aβ evoke immediate cellular Ca2+ influx through the activation of GluN2B-containing NMDARs in primary neurons.”
Citations
Cites
1 retracted
RETRACTED ARTICLE: APP binds DR6 to trigger axon pruning and neuron death via distinct caspases
Nikolaev, A., McLaughlin, T., O’Leary, D. D. M., & Tessier-Lavigne, M. (2009) · Nature · doi:10.1038/nature07767 · Cited by 992 · cited 1×
“In contrast, N-terminal fragment of APP derived from sAPPβ may be toxic, where it can bind death receptor 6 and mediate axonal pruning and neuronal cell death [26].”
BackgroundRetractedNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013) · Cell · doi:10.1016/j.cell.2013.05.039 · Cited by 14,982
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · cited 2×
“APOE ε4 affects AD risk and age of onset dose dependently [452, 454].”
BackgroundNatural RNA circles function as efficient microRNA sponges
Hansen, T. B., Jensen, T. I., Clausen, B. H., Bramsen, J. B., Finsen, B., Damgaard, C. K., & Kjems, J. (2013) · Nature · doi:10.1038/nature11993 · Cited by 7,985
Neurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971
Dietary Modulation of the Human Colonic Microbiota: Introducing the Concept of Prebiotics
Gibson, G. R., & Roberfroid, M. B. (1995) · The Journal of Nutrition · doi:10.1093/jn/125.6.1401 · Cited by 7,667 · cited 1×
“a protective barrier which inhibits colonization of pathogenic bacteria and inhibits pathogens from adhering to intestinal cells [578].”
BackgroundDNA methylation age of human tissues and cell types
Horvath, S. (2013) · Genome Biology · doi:10.1186/gb-2013-14-10-r115 · Cited by 7,075 · cited 1×
“DNA methylation is associated with development and aging, and can be used as an epigenetic clock to predict the age of various cell and tissue types [510].”
BackgroundIliff, J. J., Wang, M., Liao, Y., Plogg, B. A., Peng, W., Gundersen, G. A., Benveniste, H., Vates, G. E., Deane, R., Goldman, S. A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003748 · Cited by 5,824 · cited 25×
“Abbreviations AD: Alzheimer’s disease; APOE: Apolipoprotein E; Aβ: β-Amyloid; APP: Amyloid precursor protein; KCC2: K-Cl cotransporter 2; GABA : γaminobutyric acid; sAPP: Soluble amyloid precursor proteins; CNS: Central nervous system; PS1/2: Presenilins 1/2; CSF: Cerebral spinal fluid; LRP1: Lowdensity lipoprotein re…”
BackgroundInfluentialA Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493 · cited 1×
“DAM features unique transcriptional and functional characteristics [317], and are associated with altered expression of several genetic AD risk factors: apolipoprotein E (APOE), TREM2, progranulin and TYROBP (DAP12) are upregulated in DAM, whereas CD33, BIN1, PICALM and PLCG2 are downregulated [317–321].”
Background
Research works printed but not linked: 1
- Faraco G, et al. Dietary salt induces cognitive impairment by promoting tau pathology. Ann Neurol. 2019;86:S134.
Cited by
Mitochondrial dysfunction: mechanisms and advances in therapy
Zong, Y., Li, H., Liao, P., Chen, L., Pan, Y., Zheng, Y., Zhang, C., Liu, D., Zheng, M., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01839-8 · Cited by 1,172
“233,234 A β protein triggered mitochondrial fi ssion, synaptic loss, and neuronal damage, at least partially via S-nitrosylation of Drp1 to activate GTPase activity.”
BackgroundZhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“182,479,480 In the extensively researched A β hypothesis, A β stands as the most direct drug target.”
BackgroundApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C.-C. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00574-4 · Cited by 756
“At the cellular level, AD is characterized by synaptic dysfunction and neurodegeneration, neuroinflammation, as well as vascular dysfunction [5, 6].”
BackgroundTau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation
Chen, Y., & Yu, Y. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02853-3 · Cited by 516
“Most AD cases are LOAD, a complex disease with heterogeneous etiologies including genetics, aging, environment, lifestyle, and chronic diseases, such as obesity [6].”
BackgroundTraumatic Brain Injury and Risk of Neurodegenerative Disorder
Brett, B. L., Gardner, R. C., Godbout, J., Dams-O’Connor, K., & Keene, C. D. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.05.025 · Cited by 430
Metadata
- Authors
- Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y.
- Affiliations
- Xiamen University (CN)
- Sanford Burnham Prebys Medical Discovery Institute (US)
- Corresponding author
- Huang, Timothy Y.
- Xu, Huaxi
- Zhao, Yingjun
- Venue
- Molecular Neurodegeneration
- Published
- 2020-07-16
- Volume
- 15
- Issue
- 1
- Pages
- 40-40
- ISSN
- 1750-1326 (ISSN-L)
- PMC
- PMC7364557
- OpenAlex
- W3042981350
- Semantic Scholar
- 9d0c9bccae6d6e0750c119c605d172661f0365b1
- Cited by
- 994
- References
- 661
- Citations by year
- 2026: 114 · 2025: 194 · 2024: 211 · 2023: 158 · 2022: 180 · 2021: 122 · 2020: 15
- FWCI
- 15.62
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Molecular Neurodegeneration (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta, tau protein, glial dysfunction, apolipoprotein E, viral and bacterial infections, sleep, gut microbiota, aging, genetic risk factors, neurodegeneration
- MeSH terms
- Alzheimer Disease, Apolipoproteins E, Humans, Neurons, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease. https://app.cochat.ai/papers/10.1186/s13024-020-00391-7
- The paper
- Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y. (2020). Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease. Molecular Neurodegeneration. https://doi.org/10.1186/s13024-020-00391-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.